Browsing by Author "Nosten, Francois"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Open Access
    The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria
    (BioMed Central Ltd, 2008) Lee, Sue; Stepniewska, Kasia; Anstey, Nicholas; Ashley, Elizabeth; Barnes, Karen; Binh, Tran; D'Alessandro, Umberto; Day, Nicholas; de Vries, Peter; Dorsey, Grant; Guthmann, Jean-Paul; Mayxay, Mayfong; Newton, Paul; Nosten, Francois; Olliaro, Piero
    BACKGROUND:Malaria is a very important cause of anaemia in tropical countries. Anaemia is assessed either by measurement of the haematocrit or the haemoglobin concentration. For comparisons across studies, it is often necessary to derive one measure from the other. METHODS: Data on patients with slide-confirmed uncomplicated falciparum malaria were pooled from 85 antimalarial drug trials conducted in 25 different countries, to assess the haemoglobin/haematocrit relationship at different time points in malaria. Using a linear random effects model, a conversion equation for haematocrit was derived based on 3,254 measurements from various time points (ranging from day 0 to day 63) from 1,810 patients with simultaneous measurements of both parameters. Haemoglobin was also estimated from haematocrit with the commonly used threefold conversion. RESULTS: A good fit was obtained using Haematocrit = 5.62 + 2.60 * Haemoglobin. On average, haematocrit/3 levels were slightly higher than haemoglobin measurements with a mean difference (+/- SD) of -0.69 (+/- 1.3) for children under the age of 5 (n = 1,440 measurements from 449 patients). CONCLUSION: Based on this large data set, an accurate and robust conversion factor both in acute malaria and in convalescence was obtained. The commonly used threefold conversion is also valid.
  • Thumbnail Image
    Item
    Open Access
    World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs
    (BioMed Central Ltd, 2007) Price, Ric; Dorsey, Grant; Ashley, Elizabeth; Barnes, Karen; Baird, J Kevin; d'Alessandro, Umberto; Guerin, Philippe; Laufer, Miriam; Naidoo, Inbarani; Nosten, Francois; Olliaro, Piero; Plowe, Christopher; Ringwald, Pascal; Sibley, Carol; Stepniewska
    The proliferation of antimalarial drug trials in the last ten years provides the opportunity to launch a concerted global surveillance effort to monitor antimalarial drug efficacy. The diversity of clinical study designs and analytical methods undermines the current ability to achieve this. The proposed World Antimalarial Resistance Network (WARN) aims to establish a comprehensive clinical database from which standardised estimates of antimalarial efficacy can be derived and monitored over time from diverse geographical and endemic regions. The emphasis of this initiative is on five key variables which define the therapeutic response. Ensuring that these data are collected at the individual patient level in a consistent format will facilitate better data management and analytical practices, and ensure that clinical data can be readily collated and made amenable for pooled analyses. Such an approach, if widely adopted will permit accurate and timely recognition of trends in drug efficacy. This will guide not only appropriate interventions to deal with established multidrug resistant strains of malaria, but also facilitate prompt action when new strains of drug resistant plasmodia first emerge. A comprehensive global database incorporating the key determinants of the clinical response with in vitro, molecular and pharmacokinetic parameters will bring together relevant data on host, drug and parasite factors that are fundamental contributors to treatment efficacy. This resource will help guide rational drug policies that optimize antimalarial drug use, in the hope that the emergence and spread of resistance to new drugs can be, if not prevented, at least delayed.